Cidara Therapeutics

The core of Cidara's business revolves around leveraging its DFC technology to create a new generation of immunotherapies. The Cloudbreak platform facilitates the development of conjugates that can be administered infrequently, aiming to improve patient adherence and outcomes. This approach targets a market where long-acting, effective treatments are critical, particularly for vulnerable patient populations. Cidara's primary product candidate is Rezafungin (rezafungin for injection), a novel, once-weekly echinocandin being developed for the treatment and prevention of serious fungal infections like candidemia and invasive candidiasis. In 2023, the FDA approved Rezafungin, now marketed as REZZAYO™, for the treatment of candidemia and invasive candidiasis in adult patients with limited or no alternative treatment options. This approval marked a major achievement for the company.

Cidara's business model is centered on research, development, and strategic collaborations for the commercialization of its product candidates. The company generates revenue through partnership agreements, which include upfront payments, milestone payments, and potential royalties on sales. A key partnership is the exclusive license agreement with Melinta Therapeutics for the commercialization of REZZAYO™ in the United States. For markets outside the U.S., Cidara has established agreements with other pharmaceutical companies, such as Mundipharma, to handle commercialization, allowing Cidara to focus on its core competency of drug development. The company is also advancing its pipeline to include treatments for oncology, underscoring its commitment to addressing unmet medical needs across different therapeutic areas.